The DOI matches its Crossref record; 274 of the 274 references it cites were found in a registry or an index.
Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
Open accessAbstract
Cancer cells alter metabolic processes to sustain their characteristic uncontrolled growth and proliferation. These metabolic alterations include (1) a shift from oxidative phosphorylation to aerobic glycolysis to support the increased need for ATP, (2) increased glutaminolysis for NADPH regeneration, (3) altered flux through the pentose phosphate pathway and the tricarboxylic acid cycle for macromolecule generation, (4) increased lipid uptake, lipogenesis, and cholesterol synthesis, (5) upregulation of one-carbon metabolism for the production of ATP, NADH/NADPH, nucleotides, and glutathione, (6) altered amino acid metabolism, (7) metabolism-based regulation of apoptosis, and (8) the utilization of alternative substrates, such as lactate and acetate. Altered metabolic flux in cancer is controlled by tumor-host cell interactions, key oncogenes, tumor suppressors, and other regulatory molecules, including non-coding RNAs. Changes to metabolic pathways in cancer are dynamic, exhibit plasticity, and are often dependent on the type of tumor and the tumor microenvironment, leading in a shift of thought from the Warburg Effect and the “reverse Warburg Effect” to metabolic plasticity. Understanding the complex nature of altered flux through these multiple pathways in cancer cells can support the development of new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–274 of 274
Erratum: From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.131 · Cited by 101
Statins: a role in breast cancer therapy?
Borgquist, S., Bjarnadottir, O., Kimbung, S., & Ahern, T. P. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12806 · Cited by 100
Acetate Fuels the Cancer Engine
Lyssiotis, C. A., & Cantley, L. C. (2014) · Cell · doi:10.1016/j.cell.2014.12.009 · Cited by 98
Lin, S.-T., Tu, S., Yang, P., Hsu, S., Lee, W., Ho, C., Wu, C., Lai, Y.-H., Chen, M., & Chen, L.-C. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b02861 · Cited by 96
Vázquez, A., Tedeschi, P. M., & Bertino, J. R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3709 · Cited by 95
dos Reis, L. M., Adamóski, D., Souza, R. O. O., Ascenção, C. F. R., de Oliveira, K. R. S., Corrêa‐da‐Silva, F., Patroni, F. M. D. S., Dias, M. M., Consonni, S. R., Moraes‐Vieira, P. M., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008180 · Cited by 95
Metabolism in the Tumor Microenvironment
Lau, A. N., & Heiden, M. G. V. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033333 · Cited by 95
Non-coding RNAs in the reprogramming of glucose metabolism in cancer
Shankaraiah, R. C., Veronese, A., Sabbioni, S., & Negrini, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.048 · Cited by 92
Immunometabolism in cancer at a glance
Singer, K., Cheng, W.-C., Kreutz, M. P., Ho, P., & Siska, P. J. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.034272 · Cited by 89
The natural product carolacton inhibits folate-dependent C1 metabolism by targeting FolD/MTHFD
Fu, C., Sikandar, A., Donner, J., Zaburannyi, N., Herrmann, J. E., Reck, M., Wagner‐Döbler, I., Koehnke, J., & Müller, R. (2017) · Nature Communications · doi:10.1038/s41467-017-01671-5 · Cited by 86
Novel IDH1-Targeted Glioma Therapies
Karpel‐Massler, G., Nguyen, T. T. T., Shang, E., & Siegelin, M. D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00684-6 · Cited by 86
Berruti, A., Bitossi, R., Gorzegno, G., Bottini, A., Alquati, P., Matteis, A. D., Nuzzo, F., Giardina, G., Danese, S., Lena, M. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.012 · Cited by 84
Modeling the interplay between the HIF-1 and p53 pathways in hypoxia
Zhou, C., Zhang, X., Liu, F., & Wang, W. (2015) · Scientific Reports · doi:10.1038/srep13834 · Cited by 84
Xue, P., Zeng, F., Duan, Q., Xiao, J., Liu, L., Yuan, P., Fan, L., Sun, H., Malyarenko, O. S., Lü, H., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.001 · Cited by 84
Li, W., Hao, J., Zhang, L., Cheng, Z., Deng, X., & Shu, G. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b02120 · Cited by 84
The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 84
Metabolic changes associated with methionine stress sensitivity in MDA-MB-468 breast cancer cells
Borrego, S. L., Fahrmann, J. F., Datta, R., Stringari, C., Grapov, D., Zeller, M. D., Chen, Y., Wang, P., Baldi, P., Gratton, E., et al. (2016) · Cancer & Metabolism · doi:10.1186/s40170-016-0148-6 · Cited by 78
Sayed, S. M. E., Mohamed, W. G., Seddik, M.-A. H., Ahmed, A.-S. A., Mahmoud, A. G., Amer, W. H., Nabo, M. M. H., Hamed, A., Ahmed, N. S., & Abd-Allah, A. A.-R. (2014) · 癌症:英文版 · doi:10.5732/cjc.013.10111 · Cited by 77
Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells
Shiragami, R., Murata, S., Kosugi, C., Tezuka, T., Yamazaki, M., Hirano, A., Yoshimura, Y., Suzuki, M., Shuto, K., & Koda, K. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1978 · Cited by 76
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky, A., Seltzer, M. J., & Riggins, G. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834d816a · Cited by 76
Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism
Cacace, A., Sboarina, M., Vazeille, T., & Sonveaux, P. (2017) · Oncogene · doi:10.1038/onc.2016.364 · Cited by 76
Wick, A., Bähr, O., Schüler, M., Rohrberg, K. S., Chawla, S. P., Jankú, F., Schiff, D., Heinemann, V., Narita, Y., Lenz, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4256 · Cited by 75
A second Warburg‐like effect in cancer metabolism: The metabolic shift of glutamine‐derived nitrogen
Kodama, M., & Nakayama, K. I. (2020) · BioEssays · doi:10.1002/bies.202000169 · Cited by 73
Targeting cellular metabolism to reduce head and neck cancer growth
Yang, J., Guo, Y., Seo, W., Zhang, R., Lu, C., Wang, Y. E., Luo, L., Paul, B., Yan, W., Saxena, D. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41523-4 · Cited by 72
Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy
Masamha, C. P., & LaFontaine, P. R. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26814 · Cited by 71
Curcumin directly inhibits the transport activity of GLUT1
Gunnink, L. K., Alabi, O. D., Kuiper, B. D., Gunnink, S. M., Schuiteman, S. J., Rylaarsdam, L. E., Hamilton, K. E., Wrobel, K. E., & Louters, L. L. (2016) · Biochimie · doi:10.1016/j.biochi.2016.03.014 · Cited by 70
Lipid metabolism in cancer cachexia
Dalal, S. (2018) · Annals of Palliative Medicine · doi:10.21037/apm.2018.10.01 · Cited by 67
Hong, W., Cai, P., Xu, C., Cao, D., Yu, W., Zhao, Z., Huang, M., & Jin, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00043 · Cited by 65
Nie, K., Li, J., He, X., Wang, Y., Zhao, Q., Du, M., Sun, H., Wang, J., Lyu, J., Fang, H., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0231-2 · Cited by 64
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Chapiro, J., Sur, S., Savic, L. J., Ganapathy‐Kanniappan, S., Reyes, J., Durán, R., Chettiar, S. T., Moats, C. R., Lin, M., Luo, W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1271 · Cited by 63
Dekhne, A. S., Shah, K., Ducker, G. S., Katinas, J. M., Wong-Roushar, J., Nayeen, M. J., Doshi, A., Ning, C., Bao, X., Frühauf, J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0037 · Cited by 61
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser, M., Palmisiano, N. D., Mantzaris, I., Mims, A. S., Dinardo, C. D., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C. D., Schwind, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0996-5 · Cited by 61
Schmidt, M., Voelker, H.-U., Kapp, M., Krockenberger, M., Dietl, J., & Kämmerer, U. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0652-y · Cited by 59
Dheeraj, A., Agarwal, C., Schlaepfer, I. R., Raben, D., Singh, R. P., Agarwal, R., & Deep, G. (2018) · Hypoxia · doi:10.2147/hp.s163115 · Cited by 59
Fang, Z., Jiang, C., Feng, Y., Chen, R., Lin, X., Zhang, Z., Han, L., Chen, X., Li, H., Guo, Y., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.05.016 · Cited by 58
Cysteine as a Carbon Source, a Hot Spot in Cancer Cells Survival
Serpa, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00947 · Cited by 58
Montal, E. D., Bhalla, K., Dewi, R. E., Ruiz, C. F., Haley, J. D., Ropell, A. E., Gordon, C. R., Haley, J. D., & Girnun, G. D. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0199-6 · Cited by 57
Magno, L. D., Manni, S., Pastena, F. D., Coni, S., Macone, A., Cairoli, S., Sambucci, M., Infante, P., Moretti, M., Petroni, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.024 · Cited by 57
The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling
Yamashita, A. S., Rosa, M. D. C., Stumpo, V., Rais, R., Slusher, B. S., & Riggins, G. J. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa149 · Cited by 57
Gotanda, K., Hirota, T., Matsumoto, N., & Ieiri, I. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-369 · Cited by 56
Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death
Läsche, M., Emons, G., & Gründker, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00409 · Cited by 56
Zhao, L., Huang, Y., Tian, C., Taylor, L., Curthoys, N. P., Wang, Y., Vernon, H., & Zheng, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032995 · Cited by 55
Tao, L., Wei, L., Liu, Y., Ding, Y., Liu, X., Zhang, X., Wang, X., Yao, Y., Lu, J., Wang, Q., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.001 · Cited by 54
Wang, C., Guo, K., Gao, D., Kang, X., Jiang, K., Li, Y., Sun, L., Zhang, S., Sun, C., Liu, X., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.031 · Cited by 50
Rescue of TCA Cycle Dysfunction for Cancer Therapy
Marquez, J. C., Flores, J., Kim, A. H., Nyamaa, B., Nguyen, A. T. T., Park, N., & Han, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122161 · Cited by 50
Takeuchi, Y., Nakayama, Y., Fukusaki, E., & Irino, Y. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.088 · Cited by 49
Dai, Y., Xiong, X., Huang, G., Liu, J., Sheng, S., Wang, H., & Qin, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092962 · Cited by 47
Bachelor, M. A., Lu, Y., & Owens, D. M. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.06.001 · Cited by 46
TKTL1 is overexpressed in a large portion of non-small cell lung cancer specimens
Schultz, H., Kähler, D., Branscheid, D., Vollmer, E., Zabel, P., & Goldmann, T. (2008) · Diagnostic Pathology · doi:10.1186/1746-1596-3-35 · Cited by 45
Guo, L., Zhou, B. O., Liu, Z., Xu, Y., Lü, H., Xia, M., Guo, E., Shan, W., Chen, G., & Wang, C. (2016) · Tumor Biology · doi:10.1007/s13277-016-4984-3 · Cited by 45
Evolution of GAPDH as a druggable target of tumor glycolysis?
Ganapathy‐Kanniappan, S. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1449834 · Cited by 44
Capecitabine for the treatment of pancreatic cancer
Siddiqui, N. S., Godara, A., Byrne, M. M., & Saif, M. W. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1560422 · Cited by 44
Metformin: Metabolic Rewiring Faces Tumor Heterogeneity
Cioce, M., Pulito, C., Strano, S., Blandino, G., & Fazio, V. M. (2020) · Cells · doi:10.3390/cells9112439 · Cited by 42
Seto, T., Azuma, K., Yamanaka, T., Sugawara, S., Yoshioka, H., Wakuda, K., Atagi, S., Iwamoto, Y., Hayashi, H., Okamoto, I., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01494 · Cited by 40
BCAT1 promotes proliferation of endometrial cancer cells through reprogrammed BCAA metabolism.
Wang, P., Wu, S., Zeng, X., Zhang, Y., Zhou, Y., Su, L., & Lin, W. Y. (2018) · Europe PMC (PubMed Central) · Cited by 40
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Megías‐Vericat, J. E., Ballesta‐López, O., Barragán, E., & Montesinos, P. (2019) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s177913 · Cited by 39
Two high-rate pentose-phosphate pathways in cancer cells
Cossu, V., Bonanomi, M., Bauckneht, M., Ravera, S., Righi, N., Miceli, A., Morbelli, S. D., Orengo, A. M., Piccioli, P., Bruno, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-79185-2 · Cited by 38
Glycine inhibits angiogenesis in colorectal cancer: role of endothelial cells
Bruns, H., Kazanavičius, D., Schultze, D. P., Al‐Saeedi, M., Yamanaka, K., Strupas, K., & Schemmer, P. (2016) · Amino Acids · doi:10.1007/s00726-016-2278-0 · Cited by 35
SCAP links glucose to lipid metabolism in cancer cells
Guo, D. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1132120 · Cited by 34
de Marinis, F., Rinaldi, M., Ardizzoni, A., Bruzzi, P., Pennucci, M. C., Portalone, L., DʼAprile, M., Ripanti, P., Romano, F., Belli, M., et al. (1999) · Tumori Journal · doi:10.1177/030089169908500306 · Cited by 34
Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer
Vergati, M., Krasniqi, E., Monte, G. D., Riondino, S., Vallone, D., Guadagni, F., Ferroni, P., & Roselli, M. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170116122915 · Cited by 34
Rana, R. M., Rampogu, S. D., Abid, N. B., Zeb, A., Parate, S., Lee, G., Yoon, S., Kim, Y., Kim, D. H., & Lee, K. W. (2020) · Molecules · doi:10.3390/molecules25153510 · Cited by 34
Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
Okimoto, T., Kotani, H., Iida, Y., Koyanagi, A., Tanino, R., Tsubata, Y., Isobe, T., & Harada, M. (2020) · Cancer Science · doi:10.1111/cas.14401 · Cited by 32
Bouchez, C. L., Hammad, N., Cuvellier, S., Ransac, S., Rigoulet, M., & Devin, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01333 · Cited by 32
Li, W., Zhang, S., Zhao, Y., Huang, S., & Zhao, J. (2016) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2016.11.005 · Cited by 29
Zhao, L., Huang, Y., & Zheng, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076581 · Cited by 28
Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis
Costa, I., Hennenlotter, J., Stühler, V., Kühs, U., Scharpf, M. O., Todenhöfer, T., Stenzl, A., & Bedke, J. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.06.010 · Cited by 26
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer
Rossi, G., Alama, A., Genova, C., Rijavec, E., Tagliamento, M., Biello, F., Coco, S., Bello, M. G. D., Boccardo, S., & Grossi, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1536746 · Cited by 25
Grasping for aspartate in tumour metabolism
Fu, A., & Danial, N. N. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0137-9 · Cited by 20
Terry, A. R., & Hay, N. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0146-6 · Cited by 17
Nitric Oxide And Oxygen: Actions And Interactions In Health And Disease
Moncada, P. S. S. (2015) · Redox Biology · doi:10.1016/j.redox.2015.09.034 · Cited by 16
Non-Coding RNAs Operate in the Crosstalk Between Cancer Metabolic Reprogramming and Metastasis
Li, Z., & Sun, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00810 · Cited by 14
NRF2-Mediated Gene Regulation and Glucose Homeostasis
Yagishita, Y., Uruno, A., & Yamamoto, M. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801585-8.00027-0 · Cited by 13
Prieto, D., Seija, N., Uriepero, A., Souto-Padrón, T. C. B. S., Oliver, A. C., Irigoín, V., Guillermo, C., Navarrete, M. A., Landoni, A. I., Dighiero, G., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15427 · Cited by 13
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Targeting glycolysis in non-small cell lung cancer: Promises and challenges
Xu, J.-Q., Fu, Y.-L., Zhang, J., Zhang, K.-Y., Ma, J., Tang, J.-Y., Zhang, Z.-W., & Zhou, Z.-Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1037341 · Cited by 75
The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy
Puris, E., Fricker, G., & Gynther, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020364 · Cited by 58
Metabolic reprogramming: The driving force behind cancer drug resistance
El-Sehrawy, A. A. M. A., Hsu, C.-Y., Alkhathami, A. G., Chandra, M., Basunduwah, T. S., Malathi, H., Senapati, J. N., Gautam, A., Kadhem, M., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152392 · Cited by 11
Flores-López, L. A., De la Mora-De la Mora, I., Malagón-Reyes, C. M., García-Torres, I., Martínez-Pérez, Y., López-Herrera, G., Hernández-Alcántara, G., León-Avila, G., López-Velázquez, G., Olaya-Vargas, A., et al. (2024) · Biomolecules · doi:10.3390/biom14101295 · Cited by 6
Metadata
- Authors
- Schiliro, C., & Firestein, B. L.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 1056
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3158660301
- Cited by
- 615
- References
- 274
- FWCI
- 29.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.